Survival outcomes of patients with giant cell myocarditis bridged by ventricular assist devices

Emmanouil S. Brilakis, Lyle J. Olson, Gerald J. Berry, Richard C. Daly, Daniel Loisance, Mark Zucker, Leslie T Jr. Cooper

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Giant cell myocarditis is a highly lethal disorder characterized by rapidly progressive congestive heart failure. The aim of this study was to describe the clinical course of patients with giant cell myocarditis who received a ventricular assist device. Patients with giant cell myocarditis were identified from the Multicenter Giant cell Myocarditis Registry. Bridging to cardiac transplantation in the giant cell myocarditis patients who received a ventricular assist device was compared with bridging in the general population of heart failure patients, as reported in the literature. Median posttransplantation survival for patients with giant cell myocarditis who received and did not receive ventricular assist devices was calculated by the Kaplan-Meier method and compared with use of the log-rank test. Nine patients with giant cell myocarditis who received ventricular assist devices were identified. Seven patients survived to transplantation, four were alive 30 days posttransplantation, and two survived to 1 year. The rate of successful bridging to transplantation in seven of nine patients (78%) is similar to that reported for other ventricular assist device recipients. Posttransplantation survival of 57% (4 of 7) at 30 days and 29% (2 of 7) at 1 year was significantly lower compared with 93% 1-year survival of the 30 patients with giant cell myocarditis who did not receive ventricular assist devices before transplantation (p < 0.001). Ventricular assist devices can be an effective bridge to transplantation for patients with heart failure caused by giant cell myocarditis. Although their posttransplantation survival was poor in our series, a few patients had long-term survival.

Original languageEnglish (US)
Pages (from-to)569-572
Number of pages4
JournalASAIO Journal
Volume46
Issue number5
StatePublished - Sep 2000

Fingerprint

Heart-Assist Devices
Myocarditis
Giant Cells
Survival
Transplantation
Heart Failure
Heart Transplantation
Registries

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering

Cite this

Brilakis, E. S., Olson, L. J., Berry, G. J., Daly, R. C., Loisance, D., Zucker, M., & Cooper, L. T. J. (2000). Survival outcomes of patients with giant cell myocarditis bridged by ventricular assist devices. ASAIO Journal, 46(5), 569-572.

Survival outcomes of patients with giant cell myocarditis bridged by ventricular assist devices. / Brilakis, Emmanouil S.; Olson, Lyle J.; Berry, Gerald J.; Daly, Richard C.; Loisance, Daniel; Zucker, Mark; Cooper, Leslie T Jr.

In: ASAIO Journal, Vol. 46, No. 5, 09.2000, p. 569-572.

Research output: Contribution to journalArticle

Brilakis, ES, Olson, LJ, Berry, GJ, Daly, RC, Loisance, D, Zucker, M & Cooper, LTJ 2000, 'Survival outcomes of patients with giant cell myocarditis bridged by ventricular assist devices', ASAIO Journal, vol. 46, no. 5, pp. 569-572.
Brilakis ES, Olson LJ, Berry GJ, Daly RC, Loisance D, Zucker M et al. Survival outcomes of patients with giant cell myocarditis bridged by ventricular assist devices. ASAIO Journal. 2000 Sep;46(5):569-572.
Brilakis, Emmanouil S. ; Olson, Lyle J. ; Berry, Gerald J. ; Daly, Richard C. ; Loisance, Daniel ; Zucker, Mark ; Cooper, Leslie T Jr. / Survival outcomes of patients with giant cell myocarditis bridged by ventricular assist devices. In: ASAIO Journal. 2000 ; Vol. 46, No. 5. pp. 569-572.
@article{79b4931e19c94ff3bcc66cd76b1ac7de,
title = "Survival outcomes of patients with giant cell myocarditis bridged by ventricular assist devices",
abstract = "Giant cell myocarditis is a highly lethal disorder characterized by rapidly progressive congestive heart failure. The aim of this study was to describe the clinical course of patients with giant cell myocarditis who received a ventricular assist device. Patients with giant cell myocarditis were identified from the Multicenter Giant cell Myocarditis Registry. Bridging to cardiac transplantation in the giant cell myocarditis patients who received a ventricular assist device was compared with bridging in the general population of heart failure patients, as reported in the literature. Median posttransplantation survival for patients with giant cell myocarditis who received and did not receive ventricular assist devices was calculated by the Kaplan-Meier method and compared with use of the log-rank test. Nine patients with giant cell myocarditis who received ventricular assist devices were identified. Seven patients survived to transplantation, four were alive 30 days posttransplantation, and two survived to 1 year. The rate of successful bridging to transplantation in seven of nine patients (78{\%}) is similar to that reported for other ventricular assist device recipients. Posttransplantation survival of 57{\%} (4 of 7) at 30 days and 29{\%} (2 of 7) at 1 year was significantly lower compared with 93{\%} 1-year survival of the 30 patients with giant cell myocarditis who did not receive ventricular assist devices before transplantation (p < 0.001). Ventricular assist devices can be an effective bridge to transplantation for patients with heart failure caused by giant cell myocarditis. Although their posttransplantation survival was poor in our series, a few patients had long-term survival.",
author = "Brilakis, {Emmanouil S.} and Olson, {Lyle J.} and Berry, {Gerald J.} and Daly, {Richard C.} and Daniel Loisance and Mark Zucker and Cooper, {Leslie T Jr.}",
year = "2000",
month = "9",
language = "English (US)",
volume = "46",
pages = "569--572",
journal = "ASAIO Journal",
issn = "0162-1432",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Survival outcomes of patients with giant cell myocarditis bridged by ventricular assist devices

AU - Brilakis, Emmanouil S.

AU - Olson, Lyle J.

AU - Berry, Gerald J.

AU - Daly, Richard C.

AU - Loisance, Daniel

AU - Zucker, Mark

AU - Cooper, Leslie T Jr.

PY - 2000/9

Y1 - 2000/9

N2 - Giant cell myocarditis is a highly lethal disorder characterized by rapidly progressive congestive heart failure. The aim of this study was to describe the clinical course of patients with giant cell myocarditis who received a ventricular assist device. Patients with giant cell myocarditis were identified from the Multicenter Giant cell Myocarditis Registry. Bridging to cardiac transplantation in the giant cell myocarditis patients who received a ventricular assist device was compared with bridging in the general population of heart failure patients, as reported in the literature. Median posttransplantation survival for patients with giant cell myocarditis who received and did not receive ventricular assist devices was calculated by the Kaplan-Meier method and compared with use of the log-rank test. Nine patients with giant cell myocarditis who received ventricular assist devices were identified. Seven patients survived to transplantation, four were alive 30 days posttransplantation, and two survived to 1 year. The rate of successful bridging to transplantation in seven of nine patients (78%) is similar to that reported for other ventricular assist device recipients. Posttransplantation survival of 57% (4 of 7) at 30 days and 29% (2 of 7) at 1 year was significantly lower compared with 93% 1-year survival of the 30 patients with giant cell myocarditis who did not receive ventricular assist devices before transplantation (p < 0.001). Ventricular assist devices can be an effective bridge to transplantation for patients with heart failure caused by giant cell myocarditis. Although their posttransplantation survival was poor in our series, a few patients had long-term survival.

AB - Giant cell myocarditis is a highly lethal disorder characterized by rapidly progressive congestive heart failure. The aim of this study was to describe the clinical course of patients with giant cell myocarditis who received a ventricular assist device. Patients with giant cell myocarditis were identified from the Multicenter Giant cell Myocarditis Registry. Bridging to cardiac transplantation in the giant cell myocarditis patients who received a ventricular assist device was compared with bridging in the general population of heart failure patients, as reported in the literature. Median posttransplantation survival for patients with giant cell myocarditis who received and did not receive ventricular assist devices was calculated by the Kaplan-Meier method and compared with use of the log-rank test. Nine patients with giant cell myocarditis who received ventricular assist devices were identified. Seven patients survived to transplantation, four were alive 30 days posttransplantation, and two survived to 1 year. The rate of successful bridging to transplantation in seven of nine patients (78%) is similar to that reported for other ventricular assist device recipients. Posttransplantation survival of 57% (4 of 7) at 30 days and 29% (2 of 7) at 1 year was significantly lower compared with 93% 1-year survival of the 30 patients with giant cell myocarditis who did not receive ventricular assist devices before transplantation (p < 0.001). Ventricular assist devices can be an effective bridge to transplantation for patients with heart failure caused by giant cell myocarditis. Although their posttransplantation survival was poor in our series, a few patients had long-term survival.

UR - http://www.scopus.com/inward/record.url?scp=0034282414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034282414&partnerID=8YFLogxK

M3 - Article

C2 - 11016508

AN - SCOPUS:0034282414

VL - 46

SP - 569

EP - 572

JO - ASAIO Journal

JF - ASAIO Journal

SN - 0162-1432

IS - 5

ER -